Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Clinical pharmacology and therapeutics 2021 Feb

filter terms:

Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org). © 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.

Citation

Jason H Karnes, Allan E Rettie, Andrew A Somogyi, Rachel Huddart, Alison E Fohner, Christine M Formea, Ming Ta Michael Lee, Adrian Llerena, Michelle Whirl-Carrillo, Teri E Klein, Elizabeth J Phillips, Scott Mintzer, Andrea Gaedigk, Kelly E Caudle, John T Callaghan. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clinical pharmacology and therapeutics. 2021 Feb;109(2):302-309